Patents by Inventor Chris Allan Veale
Chris Allan Veale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6939896Abstract: Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection.Type: GrantFiled: December 18, 2000Date of Patent: September 6, 2005Assignee: AstraZeneca ABInventors: Marc Jerome Chapdelaine, Katherine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
-
Publication number: 20040204390Abstract: The present invention relates to a pharmaceutical product or daily dose comprising an anti-androgen, an oestrogen receptor &bgr; (ER&bgr;) selective agonist and optionally a chemical castration agent. The invention also relates to a method of therapeutically treating and/or preventing an androgen-stimulated disease (eg, prostate cancer or benign prostate hypertrophy) in a patient. Furthermore, the invention relates to the use of an anti-androgen, an ER&bgr; selective agonist and optionally a chemical castration agent in the manufacture of a pharmaceutical product for this purpose.Type: ApplicationFiled: May 26, 2004Publication date: October 14, 2004Inventors: Barrington John Albert Furr, Anthony Nigel Brooks, Chris Allan Veale
-
Publication number: 20030207812Abstract: Substituted phenanthrene-9,10-diones in accord with structural diagram I, 1Type: ApplicationFiled: November 25, 2002Publication date: November 6, 2003Inventors: Marc Jerome Chapdelaine, Katharine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
-
Publication number: 20030130298Abstract: Heterocyclic dione compounds as disclosed in the specification, compositions thereof and methods for the use thereof, for the treatment of T cell-mediated conditions such as autoimmune diseases and organ graft rejection.Type: ApplicationFiled: November 25, 2002Publication date: July 10, 2003Inventors: Marc Jerome Chapdelaine, Katherine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
-
Publication number: 20030119897Abstract: Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Q1 at each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C1-C3) alkyl and C(O)phenyl, and Q2 is selected from hydrogen, halogen, O—(C1-C3)alkyl, O—(C1-C3)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NO2 or halogen, and indolyl may be substituted with (C1-C3)alkyl or phenyl.Type: ApplicationFiled: November 13, 2002Publication date: June 26, 2003Inventors: Marc Jerome Chapdelaine, Katherine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
-
Patent number: 6054593Abstract: The present invention relates to particular forms of a novel 1-substituted-N-[2-methyl-1-(trifluoroacetyl)propyl]pyrrolidine-2-carboxam ide which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes pharmaceutical compositions containing such forms, processes for preparing the forms and intermediates useful in the synthesis of the forms.Type: GrantFiled: June 19, 1998Date of Patent: April 25, 2000Assignee: Zeneca LimitedInventors: Chris Allan Veale, Peter Robert Bernstein, Elwyn Peter Davies
-
Patent number: 6048889Abstract: The present invention relates to particular forms of a novel 1-substituted-N-[2-methyl-1-(trifluoroacetyl)propyl]pyrrolidine-2-carboxam ide which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes pharmaceutical compositions containing such forms, processes for preparing the forms and intermediates useful in the synthesis of the forms.Type: GrantFiled: March 23, 1999Date of Patent: April 11, 2000Assignee: Zeneca LimitedInventors: Chris Allan Veale, Peter Robert Bernstein, Elwyn Peter Davies
-
Patent number: 6037363Abstract: The present invention relates to pyrrolidine derivative compounds, and more particularly to the compound (S)-1-[(S)-2-(4-methoxybenzamido)-3-methylbutyryl]-N-[(S)-2-methyl-1-(trif luoroacetyl)propyl]pyrrolidine-2-carboxamide, shown by the formula I, a pharmaceutical composition comprising this compound in a crystalline form and a process for preparing the pharmaceutical composition. The compound of formula I is an inhibitor of human neutrophil elastase and is useful in the treatment of diseases in which the enzyme is implicated, such as, for example, emphysema and acute respiratory distress syndrome (ARDS).Type: GrantFiled: February 22, 1999Date of Patent: March 14, 2000Assignee: Zeneca LimitedInventors: Stephen John Pegg, George Joseph Sependa, Elwyn Peter Davies, Chris Allan Veale
-
Patent number: 5965576Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.Type: GrantFiled: November 26, 1997Date of Patent: October 12, 1999Assignee: Zeneca LimitedInventors: Ashokkumar Bhikkappa Shenvi, Robert Toms Jacobs, Scott Carson Miller, Cyrus John Ohnmacht, Jr., Chris Allan Veale
-
Patent number: 5907043Abstract: The present invention relates to pyrrolidine derivatives, and more particularly to the compound (S)-1-?(S)-2-(4-methoxybenzamido)-3-methylbutyryl!-N-?(S)-2-methyl-1-(trif luoroacetyl)propyl!pyrrolidine-2-carboxamide, shown by formula I, and solvates thereof. The present invention also provides pharmaceutical compositions, intermediates and methods of preparation of the compound. The compound of formula I is an inhibitor of human neutrophil elastase and is useful in the treatment of diseases in which the enzyme is implicated, such as, for example, emphysema and acute respiratory distress syndrome (ARDS).Type: GrantFiled: January 27, 1998Date of Patent: May 25, 1999Assignee: Zeneca LimitedInventors: Stephen John Pegg, George Joseph Sependa, Elwyn Peter Davies, Chris Allan Veale
-
Patent number: 5808097Abstract: The present invention relates to particular forms of a novel 1-substituted-N-?2-methyl-1-(trifluoroacetyl)propyl!pyrrolidine-2-carboxam ide which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes pharmaceutical compositions containing such forms, processes for preparing the forms and intermediates useful in the synthesis of the forms.Type: GrantFiled: August 22, 1997Date of Patent: September 15, 1998Assignee: Zeneca LimitedInventors: Chris Allan Veale, Peter Robert Bernstein, Elwyn Peter Davies
-
Patent number: 5739157Abstract: The present invention relates to pyrrolidine derivatives, and more particularly to the compound (S)-1-?(S)-2-(4-methoxybenzamido)-3-methylbutyryl!-N-?(S)-2-methyl-1-(trif luoroacetyl)propyl!pyrrolidine-2-carboxamide, shown by formula I, and solvates thereof. The present invention also provides pharmaceutical compositions, intermediates and methods of preparation of the compound. The compound of formula I is an inhibitor of human neutrophil elastase and is useful in the treatment of diseases in which the enzyme is implicated, such as, for example, emphysema and acute respiratory distress syndrome (ARDS).Type: GrantFiled: July 25, 1996Date of Patent: April 14, 1998Assignee: Zeneca LimitedInventors: Stephen John Pegg, George Joseph Sependa, Elwyn Peter Davies, Chris Allan Veale
-
Patent number: 5739149Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.Type: GrantFiled: February 3, 1997Date of Patent: April 14, 1998Assignee: Zeneca LimitedInventors: Robert Toms Jacobs, Scott Carson Miller, Ashokkumar Bhikkappa Shenvi, Cyrus John Ohnmacht, Jr., Chris Allan Veale
-
Patent number: 5736535Abstract: The present invention relates to certain novel substituted derivatives which are 1-pyrimidinylacetamide derivatives of formula I, ##STR1## which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these substituted derivatives, processes for preparing the substituted derivatives, pharmaceutical compositions containing such substituted derivatives and methods for their use.Type: GrantFiled: January 19, 1995Date of Patent: April 7, 1998Assignee: Zeneca LimitedInventors: Peter Robert Bernstein, Philip Duke Edwards, Andrew Shaw, Ashokkumar Bhikkappa Shenvi, Royston Martin Thomas, Chris Allan Veale, Peter Warner, Donald John Wolanin
-
Patent number: 5721222Abstract: The present invention relates to certain novel heterocyclic ketones which are 1-pyridylacetamide ketones of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic ketones, processes for preparing the heterocyclic ketones, pharmaceutical compositions containing such heterocyclic ketones and methods for their use.Type: GrantFiled: August 25, 1995Date of Patent: February 24, 1998Assignee: ZENECA LimitedInventors: Peter Robert Bernstein, Andrew Shaw, Royston Martin Thomas, Chris Allan Veale, Peter Warner, Donald John Wolanin
-
Patent number: 5705505Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.Type: GrantFiled: September 26, 1996Date of Patent: January 6, 1998Assignee: Zeneca LimitedInventors: Ashokkumar Bhikkappa Shenvi, Robert Toms Jacobs, Scott Carson Miller, Cyrus John Ohnmacht, Jr., Chris Allan Veale
-
Patent number: 5686628Abstract: The present invention relates to particular forms of a novel 1-substituted-N-?2-methyl-1-(trifluoroacetyl)propyl!pyrrolidine-2-carboxam ide which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes pharmaceutical compositions containing such forms, processes for preparing the forms and intermediates useful in the synthesis of the forms.Type: GrantFiled: February 2, 1996Date of Patent: November 11, 1997Assignee: Zeneca Ltd.Inventors: Chris Allan Veale, Peter Robert Bernstein, Elwyn Peter Davies